【摘要】 目的 觀察利膽清微丸治療慢性膽囊炎濕熱蘊結(jié)兼血瘀證患者的療效及安全性，進一步為臨床研究提供依據(jù)?！》椒ā?001年4—7月，采用雙盲、雙模擬、隨機平行對照臨床試驗，將40例患者隨機分為試驗組（20例）及對照組（20例）。試驗組服用利膽清微丸3.5 g/次，3次/d，同時服用膽寧片模擬劑；對照組服用膽寧片3片/次，3次/d，同時服用利膽清微丸模擬劑。 結(jié)果 試驗組痊愈1例，顯效12例，有效5例，無效2例，顯效率65%，有效率90%；對照組痊愈2例，顯效10例，有效7例，無效1例，顯效率60%，有效率95%，兩組療效比較差異無統(tǒng)計學意義（Pgt;0.05）。試驗過程中未發(fā)現(xiàn)明顯不良反應。 結(jié)論 利膽清微丸對于治療慢性膽囊炎濕熱蘊結(jié)兼血瘀證有良好效果，是一種安全有效的藥物?！続bstract】 Objective To observe the safety and efficacy of Lidanqing pellet on chronic cholecystitis with damp and hot accumulate knot including blood stasis, and to provide a basis for further clinical trials. Methods A double-blind, double dummy, randomized, and controlled clinic trial was undertaken between April and July 2001. A total of 40 patients were randomly divided into trail group and control group. The trial group was given Lidanqin pellet 3.5 g per time, and three times per day; simultaneously taking Danning tablet simulation agent. The control group was given 3 tablets of Danning tablet per time and three times per day; simultaneously taking taking Lidanqing pellets simulation agent. Results In the trail group, one patient was cured, the therapeutic effect was obvious in 12, basically effective in five and invalid in two (with the rate of obvious effect of 65.00% and rate of basic effect of 90.00%). In the control group, two patients was cured, the therapeutic effect was obvious in 12, basically effective in 10, effective in seven and invalid in one (with the rate of basic effect of 60.00% and the rate of obvious effect of 95.00%). The difference between the two groups was significant (Pgt;0.05). Adverse reaction was not found in the trial group. Conclusion Lidanqing pellet, a safe medication, is effective on chronic cholecystitis with damp and hot accumulate knot including blood stasis.